HomeCompareOPORF vs MAIN

OPORF vs MAIN: Dividend Comparison 2026

OPORF yields 3.14% · MAIN yields 8.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $32.7K in total portfolio value
10 years
OPORF
OPORF
● Live price
3.14%
Share price
$0.09
Annual div
$0.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$384.28
Full OPORF calculator →
MAIN
Main Street Capital Corporation
● Live price
8.41%
Share price
$52.80
Annual div
$4.44
5Y div CAGR
5.1%
Payout ratio
82%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.2K
Annual income
$2,355.47
Full MAIN calculator →

Portfolio growth — OPORF vs MAIN

📍 MAIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOPORFMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OPORF + MAIN cover 8 of 12 monthsgood coverage

Jan
MAIN
Feb
MAIN
Mar
Apr
May
Jun
Jul
MAIN
Aug
MAIN
Sep
MAIN
Oct
MAIN
Nov
MAIN
Dec
MAIN
OPORF pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OPORF
Annual income on $10K today (after 15% tax)
$266.85/yr
After 10yr DRIP, annual income (after tax)
$326.64/yr
MAIN
Annual income on $10K today (after 15% tax)
$714.77/yr
After 10yr DRIP, annual income (after tax)
$2,002.15/yr
At 15% tax rate, MAIN beats the other by $1,675.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OPORF + MAIN for your $10,000?

OPORF: 50%MAIN: 50%
100% MAIN50/50100% OPORF
Portfolio after 10yr
$40.8K
Annual income
$1,369.88/yr
Blended yield
3.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

OPORF
No analyst data
Altman Z
3.9
Piotroski
6/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+23.6% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OPORF buys
0
MAIN buys
0
No recent congressional trades found for OPORF or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOPORFMAIN
Forward yield3.14%8.41%
Annual dividend / share$0.00$4.44
Payout ratio50%82%
1-year div growth0%3.7%
5-year div CAGR0%5.1%
Portfolio after 10y$24.5K$57.2K
Annual income after 10y$384.28$2,355.47
Total dividends collected$3.5K$15.5K
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: OPORF vs MAIN ($10,000, DRIP)

YearOPORF PortfolioOPORF Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$11,014$313.94$12,124$883.80$1.1KMAIN
2$12,108$323.15$14,629$1,001.91$2.5KMAIN
3$13,288$332.01$17,573$1,130.42$4.3KMAIN
4$14,558$340.52$21,022$1,269.75$6.5KMAIN
5$15,926$348.67$25,049$1,420.29$9.1KMAIN
6$17,397$356.48$29,738$1,582.45$12.3KMAIN
7$18,979$363.93$35,182$1,756.64$16.2KMAIN
8$20,679$371.05$41,488$1,943.25$20.8KMAIN
9$22,504$377.83$48,775$2,142.72$26.3KMAIN
10$24,464$384.28$57,179$2,355.47$32.7KMAIN

OPORF vs MAIN: Complete Analysis 2026

OPORFStock

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Full OPORF Calculator →

MAINBDC

Main Street Capital is a Business Development Company providing debt and equity capital to lower middle market companies. It pays regular monthly dividends plus semi-annual special dividends. One of the few BDCs consistently trading at a premium to NAV, with an exceptional track record since its 2007 IPO. Often called the gold standard of BDCs.

Full MAIN Calculator →
📬

Get this OPORF vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OPORF vs SCHDOPORF vs JEPIOPORF vs OOPORF vs KOOPORF vs ARCCOPORF vs HTGCOPORF vs GBDCOPORF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.